Switch theme
Sign up to access all valuation multiples
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
2014
8
LTM Revenue $1.3M
LTM EBITDA -$4.2M
$5.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
NextCell Pharma has a last 12-month revenue (LTM) of $1.3M and a last 12-month EBITDA of -$4.2M.
In the most recent fiscal year, NextCell Pharma achieved revenue of $1.1M and an EBITDA of -$4.2M.
NextCell Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NextCell Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.3M | XXX | $1.1M | XXX | XXX | XXX |
| Gross Profit | $1.3M | XXX | -$0.5M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | -43% | XXX | XXX | XXX |
| EBITDA | -$4.2M | XXX | -$4.2M | XXX | XXX | XXX |
| EBITDA Margin | -327% | XXX | -384% | XXX | XXX | XXX |
| EBIT | -$4.7M | XXX | -$4.5M | XXX | XXX | XXX |
| EBIT Margin | -366% | XXX | -405% | XXX | XXX | XXX |
| Net Profit | n/a | XXX | -$4.3M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | -393% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, NextCell Pharma's stock price is SEK 1 (or $0).
NextCell Pharma has current market cap of SEK 78.9M (or $8.1M), and EV of SEK 52.6M (or $5.4M).
See NextCell Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.4M | $8.1M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, NextCell Pharma has market cap of $8.1M and EV of $5.4M.
NextCell Pharma's trades at 4.6x EV/Revenue multiple, and -1.3x EV/EBITDA.
Equity research analysts estimate NextCell Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NextCell Pharma's P/E ratio is not available.
See valuation multiples for NextCell Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.1M | XXX | $8.1M | XXX | XXX | XXX |
| EV (current) | $5.4M | XXX | $5.4M | XXX | XXX | XXX |
| EV/Revenue | 4.2x | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | -1.3x | XXX | -1.3x | XXX | XXX | XXX |
| EV/EBIT | -1.1x | XXX | -1.2x | XXX | XXX | XXX |
| EV/Gross Profit | 4.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | -1.4x | XXX | -1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNextCell Pharma's last 12 month revenue growth is 20%
NextCell Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.5M for the same period.
NextCell Pharma's rule of 40 is -367% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NextCell Pharma's rule of X is -277% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for NextCell Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 211% | XXX | XXX | XXX |
| EBITDA Margin | -327% | XXX | -357% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -367% | XXX | -337% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -277% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 362% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NextCell Pharma acquired XXX companies to date.
Last acquisition by NextCell Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . NextCell Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was NextCell Pharma founded? | NextCell Pharma was founded in 2014. |
| Where is NextCell Pharma headquartered? | NextCell Pharma is headquartered in Sweden. |
| How many employees does NextCell Pharma have? | As of today, NextCell Pharma has 8 employees. |
| Is NextCell Pharma publicy listed? | Yes, NextCell Pharma is a public company listed on STO. |
| What is the stock symbol of NextCell Pharma? | NextCell Pharma trades under NXTCL ticker. |
| When did NextCell Pharma go public? | NextCell Pharma went public in 2017. |
| Who are competitors of NextCell Pharma? | Similar companies to NextCell Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of NextCell Pharma? | NextCell Pharma's current market cap is $8.1M |
| What is the current revenue of NextCell Pharma? | NextCell Pharma's last 12 months revenue is $1.3M. |
| What is the current revenue growth of NextCell Pharma? | NextCell Pharma revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of NextCell Pharma? | Current revenue multiple of NextCell Pharma is 4.2x. |
| Is NextCell Pharma profitable? | Yes, NextCell Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of NextCell Pharma? | NextCell Pharma's last 12 months EBITDA is -$4.2M. |
| What is NextCell Pharma's EBITDA margin? | NextCell Pharma's last 12 months EBITDA margin is -327%. |
| What is the current EV/EBITDA multiple of NextCell Pharma? | Current EBITDA multiple of NextCell Pharma is -1.3x. |
| What is the current FCF of NextCell Pharma? | NextCell Pharma's last 12 months FCF is -$3.9M. |
| What is NextCell Pharma's FCF margin? | NextCell Pharma's last 12 months FCF margin is -302%. |
| What is the current EV/FCF multiple of NextCell Pharma? | Current FCF multiple of NextCell Pharma is -1.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
